Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)

NCT03504566 · clinicaltrials.gov ↗

PHASE4

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Registered and published incorrectly

Conditions

Diabetic Nephropathy Type 2

Interventions

DRUG: Linagliptin
DRUG: Empagliflozin
DRUG: Telmisartan
DRUG: Sulodexide

Sponsor

Steno Diabetes Center Copenhagen

Collaborators

[object Object]